No Data
TIGERMED (03347.HK) spent 0.168 billion yuan to repurchase 3.4081 million A shares on January 27.
Glory Exchange reported on January 27 that TIGERMED (03347.HK) announced the repurchase of 3.4081 million A shares at a cost of 0.168 billion yuan on January 27.
Nomura: Maintains a "Neutral" rating on TIGERMED (03347) as the company reports a loss for the first time in recent years.
Maintain a "Neutral" rating for TIGERMED (03347), with a Target Price of HKD 28.56.
TIGERMED (03347.HK): As of January 24, a total of 3.8071 million A-shares have been repurchased.
On January 27, Gelonghui reported that TIGERMED (03347.HK) announced that as of January 24, 2025, the company's share buyback dedicated securities account has cumulatively repurchased 3.8071 million A shares of the company through centralized bidding, accounting for 0.4402% of the company's total share capital and 0.5132% of the total A share capital of the company, with the highest Fill Price being 55.30 yuan/share, the lowest Fill Price being 48.17 yuan/share, and the total transaction amount approximately 0.199 billion yuan (excluding transaction fees).
Hangzhou Tigermed Consulting: Higher R&D Costs, Increased Competition in Biopharma Industry Hurt Results >300347.SZ
Hangzhou Tigermed Consulting Sees Significant Decline in 2024 Net >300347.SZ
Hangzhou Tigermed Consulting Sees 2024 Net CNY380.0M-Net CNY570.0M >300347.SZ
